share_log

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

每日生物技术脉搏:辉瑞-BioNTech 的 COVID-19 儿童版 Booster 即将上市,Ultragenyx 批准了遗传性疾病基因疗法,Ampio 的 AP-013 试验正在独立调查中
Benzinga Real-time News ·  2022/05/17 09:09
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去24小时生物技术领域的热门发展综述:
Stocks In Focus
关注的股票
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
美国食品和药物管理局可能很快批准辉瑞-生物科技的新冠肺炎助推器用于5-11岁儿童:纽约时报
The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE:PFE)/BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine for children ages 5 to 11, likely Tuesday, the New York Times reported, citing people familiar with the matter.
美国食品和药物管理局预计将授权加强注射。辉瑞(纽约证券交易所市场代码:PFE)/BioNTech SE‘s纽约时报援引知情人士的话报道,中国(纳斯达克代码:BNTX)为5岁至11岁的儿童接种新冠肺炎疫苗,可能会在周二。
It is unclear how much demand there is for the third dose in the age group. According to the U.S. Centers for Disease Control and Prevention, just 28.8% of children ages...
目前尚不清楚该年龄段的第三剂疫苗的需求量有多大。根据美国疾病控...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发